Aurora Cannabis Inc. is rated a Buy with 40% upside in current levels and expects solid growth in medical cannabis sales.

Aurora Cannabis reports Q2-2026 revenue growth with stronger international sales but posts net loss and negative free cash flow. Learn why ACB stock is a hold.

Aurora Cannabis (ACB) delivered earnings and revenue surprises of +200.00% and +2.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Detailed price information for Aurora Cannabis Inc (ACB-Q) from The Globe and Mail including charting and trades.

Detailed price information for Aurora Cannabis Inc (ACB-Q) from The Globe and Mail including charting and trades.

What Happened? Shares of cannabis company Tilray Brands (NASDAQ:TLRY) fell 1.8% in the morning session after the U.S.

Haywood Capital Markets analyst Neal Gilmer said 2026 is shaping up to be a strong year for Rubicon Organics ( Rubicon ...

Rubicon Organics ( ($TSE:ROMJ) ) has issued an update. Rubicon Organics has appointed Glen Ibbott as its Chief Financial Officer and Corporate ...

Shares of Aurora Cannabis Inc. ACB slid 2.24% to $4.36 Thursday, on what proved to be an all-around poor trading session for ...

Aurora Cannabis (TSX:ACB) remains unprofitable, but has managed to reduce its losses at an impressive rate of 61.2% per year ...

Shares of Aurora Cannabis Inc. ACB slid 1.76% to $4.46 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.65% to ...